EA201990427A1 - RNAi AGENTS AGAINST INFECTION CAUSED BY HEPATITIS B VIRUS - Google Patents

RNAi AGENTS AGAINST INFECTION CAUSED BY HEPATITIS B VIRUS

Info

Publication number
EA201990427A1
EA201990427A1 EA201990427A EA201990427A EA201990427A1 EA 201990427 A1 EA201990427 A1 EA 201990427A1 EA 201990427 A EA201990427 A EA 201990427A EA 201990427 A EA201990427 A EA 201990427A EA 201990427 A1 EA201990427 A1 EA 201990427A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hbv
agents
hepatitis
virus
gene expression
Prior art date
Application number
EA201990427A
Other languages
Russian (ru)
Inventor
Чжэнь Ли
Жуй Чжу
Кристин И. Вудделл
Брюс Д. Гивен
Тао Пэй
Дэвид Л. Луис
Лорен Дж. Алмеда
Дэвид Б. Розема
Даррен Х. Уэйкфилд
Original Assignee
Эрроухед Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эрроухед Фармасьютикалс, Инк. filed Critical Эрроухед Фармасьютикалс, Инк.
Priority claimed from PCT/US2017/045446 external-priority patent/WO2018027106A2/en
Publication of EA201990427A1 publication Critical patent/EA201990427A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описаны композиции и способы ингибирования экспрессии гена вируса гепатита B. Описаны агенты РНК-интерференции (РНКи) для ингибирования экспрессии гена вируса гепатита B. Агенты РНКи против ВГВ, описанные в настоящем документе, могут быть нацелены на клетки, такие как гепатоциты, например, с использованием конъюгированных нацеливающих лигандов. Также описаны фармацевтические композиции, содержащие один или более агентов РНКи против ВГВ и необязательно один или более дополнительных терапевтических средств. Доставка описанных агентов РНКи против ВГВ в инфицированную печень in vivo обеспечивает ингибирование экспрессии гена ВГВ и лечение заболеваний и состояний, связанных с инфекцией ВГВ.Compositions and methods for inhibiting hepatitis B virus gene expression are described. RNA interference agents (RNAi) for inhibiting hepatitis B gene expression are described. Anti-HBV RNA agents described herein can target cells such as hepatocytes, for example, with using conjugated targeting ligands. Also described are pharmaceutical compositions containing one or more anti-HBV RNA agents and optionally one or more additional therapeutic agents. In vivo delivery of the described anti-HBV RNAi agents to the infected liver in vivo provides inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.

EA201990427A 2017-08-03 2017-08-04 RNAi AGENTS AGAINST INFECTION CAUSED BY HEPATITIS B VIRUS EA201990427A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762540639P 2017-08-03 2017-08-03
PCT/US2017/045446 WO2018027106A2 (en) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION

Publications (1)

Publication Number Publication Date
EA201990427A1 true EA201990427A1 (en) 2019-08-30

Family

ID=67734935

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990427A EA201990427A1 (en) 2017-08-03 2017-08-04 RNAi AGENTS AGAINST INFECTION CAUSED BY HEPATITIS B VIRUS

Country Status (1)

Country Link
EA (1) EA201990427A1 (en)

Similar Documents

Publication Publication Date Title
PH12019500245A1 (en) RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
MX2021009495A (en) Rnai agents for hepatitis b virus infection.
ZA202106265B (en) Compositions and methods for inhibiting gene expression of lpa
EA202191537A1 (en) COMPOSITIONS AND METHODS FOR INHIBITION OF HEPATITIS B VIRUS GENE EXPRESSION
EA202090514A1 (en) ANTI-VIRAL AGAINST HEPATITIS IN
EA201491179A1 (en) 2 ', 4'-DIFFOROR-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS AN INHIBITORS REPLICATION RNA HEPATITIS C VIRUS
MX2022009352A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus.
EA201791535A1 (en) NEW CONNECTION 4'-TIONOUCLEOSIDE, AND ALSO THE WAY OF ITS OBTAINING, ITS PHARMACEUTICAL COMPOSITION AND APPLICATION
EA201792103A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES
NZ628515A (en) Antiviral compounds with a dibenzooxaheterocycle moiety
JO3281B1 (en) Benzofuran Compounds for the Treatment of Hepatitis C Virus Infections
PH12021550287A1 (en) HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
EA201990427A1 (en) RNAi AGENTS AGAINST INFECTION CAUSED BY HEPATITIS B VIRUS
EA202192191A1 (en) RNAi AGENTS AGAINST HEPATITIS B VIRUS INFECTION
JO3769B1 (en) RNAi Therapy for Hepatitis B Virus Infection
AR109293A1 (en) IRN AGENTS FOR INFECTION WITH THE HEPATITIS B VIRUS
EA202090234A1 (en) RNAi MEANS FOR INHIBITING ALPHA-ENaC EXPRESSION AND METHODS OF APPLICATION
EA201892004A1 (en) ANTIVIRAL AGENTS FOR THE TREATMENT OF HEPATITIS B
EA201891427A1 (en) TARGET LIGANDS FOR THERAPEUTIC COMPOUNDS